Fragile X Syndrome and Autism Spectrum Disorders

The Neuroscience of Autism Spectrum Disorders

Volumn , Issue , 2013, Pages 409-419

  Brown, W Ted ^a   Cohen, Ira L ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882570081     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-391924-3.00030-2     Document Type: Chapter

References (123)

1. Allingham-Hawkins D.J., Babul-Hirji R., Chitayat D., Holden J.J., Yang K.T., Lee C., et al. Fragile X premutation is a significant risk factor for premature ovarian failure: The International Collaborative POF in Fragile X study - preliminary data. American Journal of Medical Genetics 1999, 83:322-325.
2. Arron K., Oliver C., Moss J., Berg K., Burbidge C. The prevalence and phenomenology of self-injurious and aggressive behavior in genetic syndromes. Journal of Intellectual Disability Research 2011, 55:109-120.
3. Ashley C.T., Wilkinson K.D., Reines D., Warren S.T. FMR1 protein: Conserved RNP family domains and selective RNA binding. Science 1993, 262:563-566.
4. Bailey D.B., Hatton D.D., Skinner M., Mesibov G. Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome. Journal of Autism and Developmental Disorders 2001, 31:165-174.
5. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends in Neuroscience 2004, 27:370-377.
6. Bennetto L., Pennington B.F. Neuropsychology. Fragile X Syndrome: Diagnosis, Treatment and Research 2002, 206-250. Johns Hopkins University Press, Baltimore, MD. third ed. R.J. Hagerman, P.J. Hagerman (Eds.).
7. Bernardet M., Crusio W.E. Fmr1 KO mice as a possible model of autistic features. Scientific World Journal 2006, 6:1164-1176.
8. Berry-Kravis E., Raspa M., Loggin-Hester L., Bishop E., Holiday D., Bailey D.B. Seizures in fragile X syndrome: Characteristics and comorbid diagnoses. American Journal of Intellectual and Developmental Disabilities 2010, 115:461-472.
9. Blomquist H.K., Bohman M., Edvinsson S.O., Gillberg C., Gustavson K.H., Holmgren G., et al. Frequency of the fragile X syndrome in infantile autism. A Swedish multicenter study. Clinical Genetics 1985, 27:113-117.
10. Bolduc F.V., Valente D., Mitra P., Tully T. An assay for social interaction in Drosophila Fragile X mutants. Fly (Austin) 2010, 4(3). [Epub ahead of print].
11. Bolton P., Rutter M., Butler L., Summers D. Females with autism and the fragile X. Journal of Autism and Developmental Disorders 1989, 19:473-476.
12. Bontekoe C.J., McIlwain K.L., Nieuwenhuizen I.M., Yuva-Paylor L.A., Nellis A., Willemsen R., et al. Knockout mouse model for Fxr2: A model for mental retardation. Human Molecular Genetics 2002, 11:487-498.
13. Brown W.T. The Molecular Biology of the Fragile X Mutation. Fragile X Syndrome: Diagnosis, Treatment and Research 2002, 110-135. Johns Hopkins University Press, Baltimore, MD. third ed. R.J. Hagerman, P.J. Hagerman (Eds.).
14. Brown W.T., Friedman E., Jenkins E.C., Brooks J., Wisniewski K., Raguthu S., et al. Association of Fragile X syndrome with autism. The Lancet 1982, 1:100.
15. Brown W.T., Jenkins E.C., Cohen I.L., Fisch G.S., Wolf-Schein E.G., Gross A., et al. Fragile X and autism: A multicenter survey. American Journal of Medical Genetics 1986, 23:341-352.
16. Brown W.T., Jenkins E.C., Friedman E., Brooks J., Wisniewski K., Raguthu S., et al. Autism is associated with the fragile-X syndrome. Journal of Autism and Developmental Disorders 1982, 12:303-308.
17. Brown W.T., Houck G., Jeziorowska A., Levinson F., Ding X.-H., Dobkin C., et al. Rapid Fragile X carrier screening and prenatal diagnosis by a non-radioactive PCR test. Journal of the American Medical Association 1993, 270:1569-1575.
18. Brown W.T., Nolin S., Houck G., Ding X., Glicksman A., Li S.-Y., et al. Prenatal diagnosis and carrier screening by PCR. American Journal of Human Genetics 1996, 64:191-195.
19. Brown W.T., Hagerman R., Rathmell B., Wang P., Carpenter R., Bear M., et al. Arbaclofen treatment is associated with global behavioral improvement in fragile X syndrome (FXS): Results of a randomized, controlled phase 2 trial. Presentation 3071 at American Society of Human Genetics 2010 meeting, Baltimore, MD 2010.
20. Budimirovic D.B., Bukelis I., Cox C., Gray R.M., Tierney E., Kaufmann W.E. Autism spectrum disorder in Fragile X syndrome: Differential contribution of adaptive socialization and social withdrawal. American Journal of Medical Genetics. Part A 2006, 140A:1814-1826.
21. Chen L., Hadd A., Sah S., Filipovic-Sadic S., Krosting J., Sekinger E., et al. An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for southern blot analysis. Journal of Molecular Diagnostics 2010, 12:589-600.
22. Chen L., Hadd A.G., Sah S., Houghton J.F., Filipovic-Sadic S., Zhang W., et al. High-resolution methylation polymerase chain reaction for fragile X analysis: Evidence for novel FMR1 methylation patterns undetected in Southern blot analyses. Genetics in Medicine 2011, 13:528-538.
23. Chonchaiya W., Au J., Schneider A., Hessl D., Harris S.W., Laird M., et al. Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Human Genetics 2011, [Epub ahead of print].
24. Clifford S., Dissanayake C., Bui Q.M., Huggins R., Taylor A.K., Loesch D.Z. Autism spectrum phenotype in males and females with Fragile X full mutation and premutation. Journal of Autism and Developmental Disorders 2007, 37:738-747.
25. Coffee B., Keith K., Albizua I., Malone T., Mowrey J., Sherman S.L., et al. Incidence of Fragile X syndrome by newborn screening for methylated FMR1 DNA. American Journal of Medical Genetics 2009, 85:503-514.
26. Cohen I.L. The behavioral phenotype of Fragile X Syndrome and its association with autism. Third International Fragile X Conference 1992, Spectra Publishing, Denver, CO. R.J. Hagerman (Ed.).
27. Cohen I.L. Behavioral profiles of autistic and non-autistic fragile X males. Developmental Brain Dysfunction 1995, 8:252-269.
28. Cohen I.L. A theoretical analysis of the role of hyperarousal in the behavior and learning of fragile X males. Mental Retardation and Developmental Disabilities Research Reviews 1996, 1:286-291.
29. Cohen I.L. Criterion-related validity of the PDD behavior inventory. Journal of Autism and Developmental Disorders 2003, 33:47-53.
30. Cohen I.L., Brown W.T., Jenkins E.C., Krawczun M.S., French J.H., Raguthu S., et al. Fragile X syndrome in females with autism. American Journal of Medical Genetics 1989, 34:302-303.
31. Cohen I.L., Fisch G.S., Sudhalter V., Wolf-Schein E.G., Hanson D., Hagerman R., et al. Social gaze, social avoidance, and repetitive behavior in Fragile X males: A controlled study. American Journal of Mental Retardation 1988, 92:436-446.
32. Cohen I.L., Liu X., Schutz C., White B.N., Jenkins E.C., Brown W.T., et al. Association of autism severity with a monoamine oxidase A functional polymorphism. Clinical Genetics 2003, 64:190-197.
33. Cohen I.L., Nolin S.L., Sudhalter V., Ding X.H., Dobkin C.S., Brown W.T. Mosaicism for the FMR1 gene influences adaptive skills development in Fragile X-affected males. American Journal of Medical Genetics 1996, 64:365-369.
34. Cohen I.L., Schmidt-Lackner S., Romanczyk R., Sudhalter V. The PDD Behavior Inventory: A rating scale for assessing response to intervention in children with pervasive developmental disorder. Journal of Autism and Developmental Disorders 2003, 33:31-45.
35. Cohen I.L., Sudhalter V., Pfadt A., Jenkins E.C., Brown W.T., Vietze P.M. Why are autism and the fragile-X syndrome associated? Conceptual and methodological issues. American Journal of Medical Genetics 1991, 48:195-202.
36. Cohen I.L., Sudhalter V. The PDD Behavior Inventory 2005, Psychological Assessment Resources, Lutz, FL.
37. Cohen I.L., Tsiouris J.A., Pfadt A. Effects of long-acting propranolol on agonistic and stereotyped behaviors in a male with pervasive developmental disorder and Fragile X syndrome: A double-blind, placebo controlled study. Journal of Clinical Psychopharmacology 1991, 11:898-899.
38. Cohen I.L., Vietze P.M., Sudhalter V., Jenkins E.C., Brown W.T. Effects of age and communication level on eye contact in Fragile X males and non-Fragile X autistic males. American Journal of Medical Genetics 1991, 38:498-502.
39. Coleman M. The Autistic Syndromes 1976, North-Holland.
40. Coleman M., Gilberg C. The Autisms 2012, Oxford University Press, New York.
41. Collins S.C., Bray S.M., Suhl J.A., Cutler D.J., Coffee B., Zwick M.E., et al. Identification of novel FMR1 variants by massively parallel sequencing in developmentally delayed males. American Journal of Medical Genetics. Part A 2010, 52A:2512-2520.
42. Coy,.J F., Sedlacek Z., Bachner D., Hameister H., Joos S., Lichter P., et al. Highly conserved 3'UTR and expression pattern of FXR1 points to a divergent gene regulation of FXR1 and FMR1. Human Molecular Genetics 1995, 4:2209-2218.
43. Crawford D.C., Acuña J.M., Sherman S.L. Fmr1 and the fragile X syndrome: Human genome epidemiology review. Genetics in Medicine 2001, 3:359-371.
44. den Broeder M.J., van der Linde H., Brouwer J.R., Oostra B.A., Willemsen R., Ketting R.F. Generation and characterization of Fmr1 knockout zebrafish. PLoS ONE 2009, 4:e7910.
45. de Vries B.B., Mohkamsing S., van den Ouweland A.M., Halley D.J., Niermeijer M.F., Oostra B.A., et al. Screening with the FMR1 protein test among mentally retarded males. Human Genetics 1998, 103:520-522.
46. de Vrij F.M., Levenga J., van der Linde H.C., Koekkoek S.K., De Zeeuw C.I., Nelson D.L., et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiology of Disease 2008, 31:127-132.
47. D'Hulst C., De Geest N., Reeve S.P., Van Dam D., De Deyn P.P., Hassan B.A., et al. Decreased expression of the GABAA receptor in Fragile X syndrome. Brain Research 2006, 1121:238-245.
48. Dissanayake C., Bui Q., Bulhak-Paterson D., Huggins R., Loesch D.Z. Behavioral and cognitive phenotypes in idiopathic autism versus autism associated with Fragile X syndrome. Journal of Child Psychology and Psychiatry 2009, 50:290-299.
49. Dockendorff T.C., Su H.S., McBride S.M., Yang Z., Choi C.H., Siwicki K.K., et al. Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron 2002, 34:973-984.
50. Dolen G., Osterweil E., Rao B.S., Smith G.B., Auerbach B.D., Chattarji S., et al. Correction of Fragile X syndrome in mice. Neuron 2007, 56:955-962.
51. Fmr1 knockout mice: A model to study fragile X mental retardation. Cell 1994, 78:23-33. Dutch-Belgian Fragile X Consortium.
52. Edwards D.R., Keppen L.D., Ranells J.D., Gollin S.M. Autism in association with Fragile X syndrome in females: Implications for diagnosis and treatment in children. Neurotoxicology 1988, 9:359-365.
53. El Idrissi, Ding A., X.H., Scalia J., Trenkner E., Brown W.T., Dobkin C. Decreased GABA(A) receptor expression in the seizure-prone Fragile X mouse. Neuroscience Letters 2005, 377:141-146.
54. Farzin F., Perry H., Hessl D., Loesch D., Cohen J., Bacalman S., et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the Fragile X premutation. Journal of Developmental and Behavioral Pediatrics 2006, 27:S137-S144.
55. Fatemi S.H., Folsom T.D., Kneeland R.E., Liesch S.B. Metabotropic glutamate receptor 5 upregulation in children with autism is associated with underexpression of both Fragile X mental retardation protein and GABAA receptor beta 3 in adults with autism. Anatomical Record (Hoboken) 2011, 294:1635-1645.
56. Filipovic-Sadic S., Sah S., Chen L., Krosting J., Sekinger E., Zhang W., et al. A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in Fragile X syndrome. Clinical Chemistry 2010, 56:399-408.
57. Friedman E. The autistic syndrome and phenylketonuria. Schizophrenia 1969, 1:249-261.
58. Garcia-Nonell C., Ratera E.R., Harris S., Hessl D., Ono M.Y., Tartaglia N., Marvin E., et al. Secondary medical diagnosis in Fragile X syndrome with and without autism spectrum disorder. American Journal of Medical Genetics. Part A 2008, 146A:1911-1916.
59. Gasparini F., Lingenhohl K., Stoehr N. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999, 38:1493-1503.
60. Gillberg C. Identical triplets with infantile autism and the fragile-X syndrome. British Journal of Psychiatry 1983, 143:256-260.
61. Godler D.E., Tassone F., Loesch D.Z., Taylor A.K., Gehling F., Hagerman R.J., et al. Methylation of novel markers of Fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio. Human Molecular Genetics 2010, 191:618-1632.
62. Gothelf D., Furfaro J.A., Hoeft F., Eckert M.A., Hall S.S., O'Hara R., et al. Neuroanatomy of Fragile X syndrome is associated with aberrant behavior and the Fragile X mental retardation protein (FMRP). Annals of Neurology 2008, 63:40-51.
63. Gross C., Berry-Kravis E.M., Bassell G.J. Therapeutic strategies in Fragile X syndrome: Dysregulated mGluR signaling and beyond. Neuropsychopharmacology 2011, July, 1-18 [Epub].
64. Hagerman P.J. The Fragile X prevalence paradox. Medical Genetics 2008, 45:498-499.
65. Hagerman R.J. The Physical and Behavioral Phenotype. Fragile X Syndrome: Diagnosis, Treatment and Research 2002, 3-109. Johns Hopkins University Press, Baltimore. third ed. R.J. Hagerman, P.J. Hagerman (Eds.).
66. Hagerman R., Au J., Hagerman P. FMR1 premutation and full mutation molecular mechanisms related to autism. Journal of Neurodevelopmental Disorders 2011, 3:211-224.
67. Hall S.S., Lightbody A.A., Hirt M., Rezvani A., Reiss A.L. Autism in Fragile X syndrome: A category mistake?. Journal of the American Academy of Child & Adolescent Psychiatry 2010, 49:921-933.
68. Hall S.S., Lightbody A.A., Huffman L.C., Lazzeroni L.C., Reiss A.L. Physiological correlates of social avoidance behavior in children and adolescents with Fragile X syndrome. Journal of the American Academy of Child & Adolescent Psychiatry 2009, 48:320-329.
69. Hantash F.M., Goos D.M., Crossley B., Anderson B., Zhang K., Sun W., et al. FMR1 premutation carrier frequency in patients undergoing routine population-based carrier screening: Insights into the prevalence of Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome, and Fragile X-associated primary ovarian insufficiency in the United States. Genetics in Medicine 2011, 13:39-45.
70. Happe F., Ronald A. The 'fractionable autism triad': A review of evidence from behavioral, genetic, cognitive and neural research. Neuropsychological Reviews 2008, 18:287-304.
71. Harris S.W., Hessl D., Goodlin-Jones B., Ferranti J., Bacalman S., Barbato I., et al. Autism profiles of males with Fragile X syndrome. American Journal of Mental Retardation 2008, 113:427-438.
72. Hazlett H.C., Poe M.D., Lightbody A.A., Gerig G., Macfall J.R., Ross A.K., et al. Teasing apart the heterogeneity of autism: Same behavior, different brains in toddlers with Fragile X syndrome and autism. Journal of Neurodevelopmental Disorders 2009, 1:81-90.
73. Heilman K.J., Harden E.R., Zageris D.M., Berry-Kravis E., Porges S.W. Autonomic regulation in Fragile X syndrome. Developmental Psychobiology 2011, 53:785-795.
74. Hessl D., Rivera S., Koldewyn K., Cordeiro L., Adams J., Tassone F., et al. Amygdala dysfunction in men with the Fragile X premutation. Brain 2007, 130:404-416.
75. Hessl D., Tassone F., Cordeiro L., Koldewyn K., McCormick C., Green C., et al. Brief report: Aggression and stereotypic behavior in males with Fragile X syndrome-moderating secondary genes in a 'single gene' disorder. Journal of Autism and Developmental Disorders 2008, 38:184-189.
76. Hessl D., Wang J.M., Schneider A., Koldewyn K., Le L., Iwahashi C., et al. Decreased Fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the Fragile X premutation. Biological Psychiatry 2011, 70:859-865.
77. Hill M.K., Archibald A.D., Cohen J., Metcalfe S.A. A systematic review of population screening for Fragile X syndrome. Genetics in Medicine 2010, 12:396-410.
78. Hinton V.J., Brown W.T., Wisniewski K., Rudelli R.D. Analysis of neocortex in three males with the Fragile X Syndrome. American Journal of Medical Genetics 1991, 411:289-294.
79. Huber K.M., Gallagher S.M., Warren S.T., Bear M.F. Altered synaptic plasticity in a mouse model of Fragile X mental retardation. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:7746-7750.
80. Hutt C., Ounsted C. The biological significance of gaze aversion with particular reference to the syndrome of infantile autism. Behavioral Sciences 1966, 11:346-356.
81. Irwin S.A., Patel B., Idupulapati M., Harris J.B., Crisostomo R.A., Larsen B.P., et al. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: A quantitative examination. American Journal of Medical Genetics 2001, 98:161-167.
82. Iwahashi C., Tassone F., Hagerman R.J., Yasui D., Parrott G., Nguyen D., et al. A quantitative ELISA assay for the Fragile X mental retardation 1 protein. Journal of Molecular Diagnostics 2009, 11:281-289.
83. Jacquemont S., Curie A., des Portes V., Torrioli M.G., Berry-Kravis E., Hagerman R.J., et al. Epigenetic modification of the FMR1 gene in Fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Science Translational Medicine 2011, 3:64. 64ra1.
84. Jacquemont S., Hagerman R.J., Leehey M., Grigsby J., Zhang L., Brunberg J.A., et al. Fragile X premutation tremor/ataxia syndrome: Molecular, clinical, and neuroimaging correlates. American Journal of Medical Genetics 2003, 72:869-878.
85. Kanner L. Autistic disturbances of affective contact. The Nervous Child 1943, 2:217-250.
86. Karmel B.Z., Gardner J.M., Meade L.S., Cohen I.L., London E., Flory M.J., et al. Early medical and behavioral characteristics of NICU infants later classified with ASD. Pediatrics 2010, 126:457-467.
87. King M., Bearman P. Diagnostic change and the increased prevalence of autism. International Journal of Epidemiology 2009, 38:1224-1234.
88. King M.D., Bearman P.S. Socioeconomic status and the increased prevalence of autism in California. American Sociological Review 2011, 76:320-346.
89. Kirkpatrick L.L., McIlwain K.A., Nelson D.L. Comparative genomic sequence analysis of the FXR gene family: FMR1, FXR1, and FXR2. Genomics 2001, 78:169-177.
90. LaFauci G., Kascsak R., Kerr D., Kascsak R., Chen C., Hong H., et al. A highly sensitive capture immunoassay for the detection of the fragile X protein (FMRP) using the luminex platform. Abstracts of the National Fragile X Foundation Meeting 2010, Detroit, MI.
91. Le Couteur C.A., Rutter M., Lord C., Rios P., Robertson S., Holdgrafer M., et al. Autism diagnostic interview: A standardized investigator-based instrument. Journal of Autism and Developmental Disorders 1989, 19:363-387.
92. Levitas A., Hagerman R.J., Braden M., Rimland B., McBogg P., Matus I. Autism and the fragile X syndrome. Journal of Developmental and Behavioral Pediatrics 1983, 4:151-158.
93. Lewis P., Abbeduto L., Murphy M., Richmond E., Giles N., Bruno L., et al. Cognitive, language and social-cognitive skills of individuals with fragile X syndrome with and without autism. Journal of Intellectual Disability Research 2006, 50:532-545.
94. Li J., Pelletier M.R., Perez Velazquez J.L., Carlen P.L. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Molecular and Cellular Neurosciences 2002, 19:138-151.
95. Lightbody A.A., Reiss A.L. Gene, brain, and behavior relationships in Fragile X syndrome: Evidence from neuroimaging studies. Developmental Disabilities Research Reviews 2009, 15:343-352.
96. Lord C., Rutter M., DiLavore P.C., Risi S. Autism Diagnostic Observation Schedule (ADOS) 1999, Western Psychological Services, Los Angeles.
97. Lubs H.A. A marker X chromosome. American Journal of Human Genetics 1969, 21:231-244.
98. Lyon E., Laver T., Yu P., Jama M., Young K., Zoccoli M., et al. A simple, high-throughput assay for fragile X expanded alleles using triple repeat primed PCR and capillary electrophoresis. Journal of Molecular Diagnostics 2010, 12:505-511.
99. McBride S.M., Choi C.H., Wang Y., Liebelt D., Braunstein E., Ferreiro D., et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005, 45:753-764.
100. Meryash D.L., Szymanski L.S., Gerald P.S. Infantile autism associated with the fragile-X syndrome. Journal of Autism and Developmental Disorders 1982, 12:295-301.
101. Mientjes E.J., Willemsen R., Kirkpatrick L.L., Nieuwenhuizen I.M., Hoogeveen-Westerveld M., Verweij M., et al. Fxr1 knockout mice show a striated muscle phenotype: Implications for Fxr1p function in vivo. Human Molecular Genetics 2004, 13:1291-1302.
102. Morales J., Hiesinger P.R., Schroeder A.J., Kume K., Verstreken P., Jackson F.R., et al. Drosophila fragile X protein, DFXR, regulates neuronal morphology and function in the brain. Neuron 2002, 34:961-972.
103. Musumeci S.A., Bosco P., Calabrese G., Bakker C., De Sarro G.B., Elia M., et al. Audiogenic seizures susceptibility in transgenic mice with Fragile X syndrome. Epilepsia 2000, 41:19-23.
104. Nolin S., Brown W.T., Glicksman A., Houck G.E., Gargano A.D., Sullivan A., et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. American Journal of Medical Genetics 2003, 72:454-464.
105. Nowicki S.T., Tassone F., Ono M.Y., Ferranti J., Croquette M.F., Goodlin-Jones B., et al. The Prader-Willi phenotype of Fragile X syndrome. Journal of Developmental and Behavioral Pediatrics 2007, 28:133-138.
106. Nygren G., Cederlund M., Sandberg E., Gillstedt F., Arvidsson T., Carina-Gillberg I., et al. The prevalence of autism spectrum disorders in toddlers: A population study of 2-year-old Swedish children. Journal of Autism and Developmental Disorders 2011.
107. Pacey L.K., Heximer S.P., Hampson D.R. Increased GABAB receptor-mediated signaling reduces the susceptibility of Fragile X knockout mice to audiogenic seizures. Molecular Pharmacology 2009, 76:18-24.
108. Paluszkiewicz S.M., Martin B.S., Huntsman M.M. Fragile X syndrome: The GABAergic system and circuit dysfunction. Developmental Neuroscience 2011.
109. Partington M.W. The fragile X syndrome II: Preliminary data on growth and development in males. American Journal of Medical Genetics 1984, 17:175-194.
110. Pinto-Martin J.A., Levy S.E., Feldman J.F., Lorenz J.M., Paneth N., Whitaker A.H. Prevalence of autism spectrum disorder in adolescents born weighing <2000 grams. Pediatrics 2011, 128:883-891.
111. Qin M., Kang J., Burlin T.V., Jiang C., Smith C.B. Postadolescent changes in regional cerebral protein synthesis: An in vivo study in the FMR1 null mouse. Journal of Neuroscience 2005, 25:5087-5095.
112. Reyniers E., Vits L., De Boulle K., Van Roy B., Van Velzen D., de Graaff E., et al. The full mutation in the FMR-1 gene of male Fragile X patients is absent in their sperm. Nature Genetics 1991, 4:143-146.
113. Roberts J.E., Bailey D.B., Mankowski J., Ford A., Sideris J., Weisenfeld L.A., et al. Mood and anxiety disorders in females with the FMR1 premutation. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2009, 150B:130-139.
114. Robinson E.B., Koenen K.C., McCormick M.C., Munir K., Hallett V., Happé F., Plomin R., Ronald A. A multivariate twin study of autistic traits in 12-year-olds: Testing the fractionable autism triad hypothesis. Behavioral Genetics 2012, 42:245-255.
115. Schieve L.A., Rice C., Devine O., Maenner M.J., Lee L.C., Fitzgerald R., et al. Have secular changes in perinatal risk factors contributed to the recent autism prevalence increase? Development and application of a mathematical assessment model. Annals of Epidemiology 2011, 21:930-945.
116. Shen Y., Dies K.A., Holm I.A., Bridgemohan C., Sobeih M.M., Caronna E.B., et al. Clinical genetic testing for patients with autism spectrum disorders. Pediatrics 2010, 125:e727-e735.
117. Tamanini F., Kirkpatrick L.L., Schonkeren J., van Unen L., Bontekoe C., Bakker C., et al. The fragile X-related proteins FXR1P and FXR2P contain a functional nucleolar-targeting signal equivalent to the HIV-1 regulatory proteins. Human Molecular Genetics 2000, 9:1487-1493.
118. Tsiouris J.A., Brown W.T. Neuropsychiatric symptoms of Fragile X syndrome: Pathophysiology and pharmacotherapy. CNS Drugs 2004, 18:687-703.
119. Tucker B., Richards R., Lardelli M. Expression of three zebrafish orthologs of human FMR1-related genes and their phylogenetic relationships. Developmental Genes and Evolution 2004, 214:567-574.
120. Wan L., Dockendorff T.C., Jongens T.A., Dreyfuss G. Characterization of dFMR1, a Drosophila melanogaster homolog of the Fragile X mental retardation protein. Molecular and Cellular Biology 2000, 20:8536-8547.
121. Yan Q.J., Rammal M., Tranfaglia M., Bauchwitz R.P. Suppression of two major Fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005, 49:1053-1066.
122. Zhang Y., O'Connor J.P., Siomi M.C., Srinivasan S., Dutra A., Nussbaum R.L., et al. The Fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2. EMBO Journal 1995, 14:5358-5366.
123. Zhao M.G., Toyoda H., Ko S.W., Ding H.K., Wu L.J., Zhuo M. Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome. Journal of Neuroscience 2005, 25:7385-7392.